The UK is one of the best, if not the best places to conduct data-driven research. The NHS holds cradle -to-grave (longitudinal) medical records on every citizen and the data is generally held in electronic form and of a high standard.
RAIR has access to highly-sought NHS real world data sourced through a non-exclusive data license agreement. The data currently reflects a population of <1m people generating over 100k new episodes a year.
Oculair.BI™ is a best-in-class, scalable, serverless, informatics solution which provides researchers with the opportunity to visualise, understand and extract anonymised data cohorts from the data lake with applications in both AI and informing the design of conventional drug trials.
Oculair.KE™ uses statistics and AI to evaluate complex biological systems comprising scientific (genomic, drug and protein systems) real world (NHS) and other contextualising (environmental, social etc.) data sets in order to abstract relationships between seemingly unrelated pieces of information.
The ability to identify and validate new clinical hypotheses, may help to redesign and improve patient pathways; to identify new uses for approved drugs, to stratify patient populations and identify clinical endpoints to make clinical trials more efficient; to identify relative value for money between new/existing products and pathways; to identify biomarkers that may help diagnose patients sooner; and to predict drug response or adverse events enabling personalised treatment.
With offices at tech centres across Europe, Future Processing has expertise in the field of medical software development; big data engineering and machine/deep learning with particular specialisation in the development of advanced medical and image segmentation algorithms.
Vaticle's Type DB is the knowledge graph engine used to organise complex networks of data and making it queryable, by performing knowledge engineering. Type DB provides the knowledge foundation for cognitive and intelligent (e.g. AI) systems, by providing an intelligent language for modelling, transactions and analytics.
It is estimated that the annual economic burden of vision loss and vision disorders in adults costs the UK economy around £22 billion per year and in the US economy $ 139 billion.
RAIR's medical retina data lake includes two of the largest ophthalmic indications: diabetic macular oedema and neovascular (or “Wet”) age-related macular degeneration (nAMD).
The increased incidence of chronic eye disease, including diabetes and nAMD, has placed the healthcare system under significant financial and clinical pressure:
Diabetic macular oedema (DMO) and Age-related macular degeneration (AMD) account for 20% of the 1.8m new NHS presentations and 8m consultations each year and represent the major
The increased incidence of chronic eye disease, including diabetes and nAMD, has placed the healthcare system under significant financial and clinical pressure:
Diabetic macular oedema (DMO) and Age-related macular degeneration (AMD) account for 20% of the 1.8m new NHS presentations and 8m consultations each year and represent the major causes of vision loss.
However, in the UK:
67% of eye units are using locums;
85% of units are reliant on waiting list initiatives to clear backlogs and 4.2m patients are waiting to start treatment.
Anti-VEGF therapy is the first-line drug treatment for DMO and AMD. However, while far more effective than the alternatives, anti-VEGF drugs are ineffective or partially effective in 41-64% of treated patients, and in 4.5-8.8% of treated patients their eyesight actually deteriorates.
Nonetheless, anti-VEGF therapies constituted the 2nd a
Anti-VEGF therapy is the first-line drug treatment for DMO and AMD. However, while far more effective than the alternatives, anti-VEGF drugs are ineffective or partially effective in 41-64% of treated patients, and in 4.5-8.8% of treated patients their eyesight actually deteriorates.
Nonetheless, anti-VEGF therapies constituted the 2nd and 8th highest individual drug costs across the entire NHS in 2018 and, in the US, anti-VEGF therapy accounts for c.12% of Medicare Part B drug spending.
The burden of administering frequent intravitreal injections on healthcare human resources is also considerable, with each patient requiring several treatments a year, administered by a trained practitioner, most often a consultant ophthalmologist.